|Bid||0.00 x 1300|
|Ask||0.00 x 1300|
|Day's range||60.59 - 61.66|
|52-week range||42.48 - 68.34|
|Beta (5Y monthly)||0.72|
|PE ratio (TTM)||118.50|
|Earnings date||23-Jul-2020 - 27-Jul-2020|
|Forward dividend & yield||1.80 (2.96%)|
|1y target est||70.55|
European Medicines Agency Validates Bristol Myers Squibb’s Applications for Idecabtagene Vicleucel (Ide-cel, bb2121) and CC-486
NEW YORK, May 21, 2020 -- Pomerantz LLP is investigating claims on behalf of investors of Bristol-Myers Squibb Company (“Bristol-Myers” or the “Company”) (NYSE: BMY.RT). Such.
Bristol Myers Squibb strengthened its oncology lineup thanks to its acquisition of Celgene, but how well will the pharma giant perform moving forward?
Bristol Myers Squibb Research at EHA 2020 Demonstrates Continued Advances Across Multiple Blood Diseases
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Bristol-Myers Squibb (BMY) have what it takes? Let's find out.
Pfizer (NYSE: PFE) will look like a much different company within a few months as it spins off Upjohn and merges the unit with Mylan. Bristol Myers Squibb (NYSE: BMY) is still integrating Celgene after acquiring the biotech in November. Both Pfizer and BMS have seen their stocks plunge close to 30% this year then make strong rebounds.
FDA Approves Opdivo + Yervoy as First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer Whose Tumors Express PD-L1≥1%
NEW YORK, May 15, 2020 -- Pomerantz LLP is investigating claims on behalf of investors of Bristol-Myers Squibb Company (“Bristol-Myers” or the “Company”) (NYSE: BMY.RT). Such.
FDA approves Lilly's (LLY) selpercatinib for RET-altered lung and thyroid cancers and AstraZeneca (AZN)/Merck's (MRK) Lynparza for new ovarian cancer use.
U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Pomalyst® (pomalidomide) for AIDS-Related and HIV-Negative Kaposi sarcoma
These stocks -- a pharmaceutical company, a retailer, and a consumer staples name -- may keep your portfolio well-balanced during the next market crash.
Bristol-Myers' (BMY) BLA seeking approval for CAR-T therapy candidate, idecabtagene vicleucel, for treating relapsed and refractory multiple myeloma gets FDA's refusal. The company plans to re-submit the BLA by July.
BMS & bluebird bio to Present Updated Positive Results from Pivotal KarMMa Study of Ide-cel in Relapsed and Refractory Multiple Myeloma Patients
Opdivo + Yervoy with Limited Chemotherapy Significantly Improves Overall Survival vs. Chemotherapy Alone for Patients with First-Line....
Three-Year Data from CheckMate -227 Confirm Durable, Long-Term Survival Benefit for Opdivo (nivolumab) Plus Yervoy (ipilimumab) vs. Chemotherapy....
The FDA won't review a biologics license application for ide-cel until the company fills in some missing details.
Shares of bluebird bio fell 6.8% to $53 in premarket trading, while those of Bristol Myers were flat. The FDA in its so-called refusal to file letter asked for further details on the chemistry and manufacturing of the therapy, named ide-cel, but did not request any additional clinical data, the companies said. Ide-cel is one of the experimental therapies that Bristol Myers gained through its $74 billion acquisition of Celgene Corp and its approval is linked to a higher payout to Celgene investors.
BMS and bluebird bio Provide Regulatory Update on Idecabtagene Vicleucel (ide-cel, bb2121) for the Treatment of Patients with Multiple Myeloma